South Dakota’s Board of Economic Development approved a sales‑tax rebate of up to $65,804 for OmegaQuant’s laboratory in Sioux Falls, a decision that could expand high‑tech employment and strengthen the region’s biotechnology sector.
The rebate, awarded through the state’s New Frontiers program, reimburses sales and use taxes paid on research and development costs, including qualifying equipment and supplies. According to a press release from the Governor’s Office of Economic Development, the funding will support additional research aimed at developing blood‑fatty‑acid‑based algorithms to predict insulin resistance early.
OmegaQuant already receives a $1 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the U.S. Department of Health and Human Services. The company also secured a $320,864 National Eye Institute grant to develop algorithms for early prediction of macular degeneration and glaucoma.
Currently employing 12 South Dakota residents, OmegaQuant projects the addition of 14 full‑time positions over the next five years as the research program expands. The board previously awarded the company a rebate of up to $8,845.87 in October, and the new approval builds on that earlier support.
Commissioner of Economic Development Bill Even praised the project, stating, “Research and development projects like this demonstrate the potential of South Dakota companies to compete in specialized, high‑growth industries. Supporting this work helps create opportunities to bring new technologies to market while growing skilled employment and strengthening South Dakota’s biotechnology sector.”
Local officials and community leaders see the rebate as a tangible benefit for Sioux Falls residents, offering higher‑paying jobs and positioning the city as a hub for cutting‑edge medical research.
What’s next? OmegaQuant will begin allocating the rebate funds to purchase additional research equipment and expand its hiring plan. The company expects to announce new hires as the project progresses, and the Board of Economic Development will continue to monitor the initiative’s impact on the state’s biotech ecosystem.
Sources: mitchellrepublic.com